Gastroprokinetic activity of nizatidine during the digestive state in the dog and rat

The present study was undertaken to clarify a prokinetic activity of nizati dine (CAS 76963-41-2) during the digestive state as well as gastric emptyin g of a solid test meal in comparison with cimetidine (CAS 51481-61-9), famo tidine(CAS 76842-35-6) and cisapride (CAS 81098-60-4). Intravenous administ ration of nizatidine (0.3-3 mg/kg) enhanced the motility of the gastric ant rum and duodenum during the digestive state. With cimetidine (1-10 mg/kg) a nd famotidine (0.1-1 mg/kg) enhancement of gastric motility was observed on ly with the highest dose of cimetidine, and famotidine had no effect. Marke d enhancement of gastric motility was observed with cisapride (0.1-0.5 mg/k g). After intraduodenal administration of nizatidine (10 and 20 mg/kg) and cisapride (0.25 and 0-5 mg/kg), they also amplified the contractile activit y of the gastric antrum. Gastric emptying of a solid test meal was accelera ted by intraperitoneal administration of nizatidine (1-10 mg/kg) to the sam e extent as cisapride (0.1 1 mg/kg). In addition, even in a model of delaye d gastric emptying induced by clonidine, nizatidine, like cisapride, improv ed the rate of gastric emptying. Neither cimetidine (3-30 mg/kg) nor famoti dine (0.3-3 mg/kg) affected the gastric emptying of a solid meal or delayed , gastric emptying. These results suggest that nizatidine enhanced gastric motility even during the digestive state, and accelerated gastric emptying of a solid meal, similar to cisapride. Furthermore, nizatidine improved clo nidine-induced delayed gastric emptying. These prokinetic activities of niz atidine may by useful for the treatment of abdominal symptoms due to dysmot ility and delayed gastric emptying in patients with gastritis and non-ulcer dyspepsia. (NUD). In comparison with famotidine and cimetidine, nizatidine may be different from other histamine H-2-receptor antagonists and has uni que properties other than its gastric antisecretory activity.